SAB Biotherapeutics (SABS) News Today $1.75 +0.25 (+16.67%) Closing price 04:00 PM EasternExtended Trading$1.75 0.00 (-0.06%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Analyzing SAB Biotherapeutics (SABS) & Its PeersApril 23 at 2:21 AM | americanbankingnews.comContrasting SAB Biotherapeutics (SABS) and Its PeersApril 19, 2025 | americanbankingnews.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSAB Biotherapeutics price target lowered to $20 from $25 at ChardanApril 2, 2025 | markets.businessinsider.comSAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024March 31, 2025 | markets.businessinsider.comSAB BIO Reports Full Year 2024 Operating and Financial ResultsMarch 31, 2025 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31, 2025 | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29, 2025 | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 25, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comSAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To ConsiderDecember 23, 2024 | finance.yahoo.comSAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comPromising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateNovember 6, 2024 | globenewswire.comCraig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationOctober 10, 2024 | msn.comSAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash WiselySeptember 23, 2024 | finance.yahoo.comSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from OppenheimerSeptember 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)September 11, 2024 | markets.businessinsider.comSAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingSeptember 4, 2024 | globenewswire.comBuy Rating on SAB Biotherapeutics: Promising Developments in Type 1 Diabetes TreatmentAugust 29, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 10, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and SAB Biotherapeutics (SABS)August 10, 2024 | markets.businessinsider.comSABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comSAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 8, 2024 | globenewswire.comSAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 7, 2024 | finanznachrichten.deSAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 5, 2024 | globenewswire.comEx-Wells Fargo investment banker named CFO of pharma companyAugust 1, 2024 | bizjournals.comSAB BIO Appoints Lucy To as Chief Financial OfficerJuly 31, 2024 | globenewswire.comSAb Biotherapeutics Rebrands as SAB BIOJune 20, 2024 | globenewswire.comSAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsJune 18, 2024 | globenewswire.comSAB Biotherapeutics Announces Departure of Chief Financial OfficerMay 30, 2024 | globenewswire.comPharma company moves headquarters from Midwest to Miami BeachMay 25, 2024 | bizjournals.comSAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics: Strong Buy Rating on Robust Financials and Promising Diabetes Drug DevelopmentMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 DiabetesMay 21, 2024 | markets.businessinsider.comFDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | globenewswire.comSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 20, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsMay 6, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 17, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | msn.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 16, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 8, 2024 | globenewswire.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 4, 2024 | globenewswire.com Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address SABS Media Mentions By Week SABS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼0.330.74▲Average Medical News Sentiment SABS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼30▲SABS Articles Average Week Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FBIO News Today AGEN News Today DOMH News Today BOLT News Today CRIS News Today MTEM News Today AMGN News Today GILD News Today VRTX News Today REGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
